« Back to Record
Citation APA

Buisseret, L., Rottey, S., de Bono, J., Mossakowski, M., Delafontaine, B., Manickavasagar, T., Kotecki, N., Martinoli, C., Schneider, M., De Henau, O., Chevron, P., Lagerfelt, J., & Machiels, J. P. (2020). Abstract CT152: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers. Cancer research, 80(16_Supplement), CT152-CT152. doi:10.1158/1538-7445.AM2020-CT152


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/369337

Buisseret, L., Rottey, S., de Bono, J., Mossakowski, M., Delafontaine, B., Manickavasagar, T., Kotecki, N., Martinoli, C., Schneider, M., De Henau, O., Chevron, P., Lagerfelt, J., & Machiels, J. P. (2020). Abstract CT152: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers. Cancer research, 80(16_Supplement), CT152-CT152. doi:10.1158/1538-7445.AM2020-CT152